Background/Aims: The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of lipid metabolism, activated by unsaturated fatty acids. We investigated independent and interactive effects of PPAR ␥ 2 gene PPARG Pro12Ala (rs1801282) and PPAR ␣ gene PPARA Leu162Val (rs1800206) genotypes with dietary intake of fatty acids on concentrations of plasma lipids in subjects of whom 47.5% had metabolic syndrome. Methods: The RISCK study is a parallel design, randomised controlled trial. Plasma lipids were quantified at baseline after a 4-week high saturated fatty acids diet and after three parallel 24-week interventions with reference (high saturated fatty acids), high monounsaturated fatty acids and low-fat diets. Single nucleotide polymorphisms were genotyped in 466 subjects. Results: At baseline, the PPARG Ala12 allele was associated with increased plasma total cholesterol (n = 378; p = 0.04), LDL cholesterol (p = 0.05) and apoB (p = 0.05) after adjustment for age, gender and ethnicity. At baseline, PPARA Leu162Val ! PPARG Pro12Ala genotype interaction did not significantly influence plasma lipid concentrations. After dietary intervention, gene-gene interaction significantly influenced LDL cholesterol (p = 0.0002) and small dense LDL as a proportion of LDL (p = 0.005) after adjustments. Conclusions: Interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes may influence plasma LDL cholesterol concentration and the proportion as small dense LDL after a high monounsaturated fatty acids diet.
Introduction
The peroxisome proliferator-activated receptors (PPAR) are master transcriptional regulators of lipid and carbohydrate (CHO) metabolism [1] . The major natural ligands of PPAR ␥ are polyunsaturated fatty acids (PUFA) and prostanoids [2] , and PPAR ␣ responds to several fatty acids [3] , suggesting roles in transducing nutritional into metabolic signals [4] . Once activated, PPARs heterodimerise with the retinoid X-receptor and bind to specific peroxisome proliferator response elements (PPRE) in the promoter regions of target genes. Activation of PPAR ␥ 2, expressed mainly in adipose tissue, stimulates adipogenesis by regulating a subset of genes involved in fatty acid transport and synthesis of triglycerides [5] . PPAR ␣ plays an important role in liver, where it increases uptake of fatty acids and activates expression of genes involved in peroxisomal and mitochondrial ␤ -oxidation [3] . The PPARs are thus major regulators of lipid metabolism, capable of responding to nutritional status.
Variants of the PPAR ␥ 2 gene PPARG and PPAR ␣ gene PPARA may alter the function of the receptors and their response to dietary agonists. Numerous studies have investigated associations of the single nucleotide polymorphisms (SNPs) Pro12Ala (rs1801282) in PPARG and Leu162Val (rs1800206) in PPARA with variables characterising the metabolic syndrome, although the results have been equivocal. In the original study by Deeb et al. [6] , PPARG Ala12 carriers had a significantly lower BMI, but some later studies demonstrated a modest increase [7] [8] [9] [10] . Carriage of PPARA Val162 has been associated with components of the metabolic syndrome in some studies [11, 12] but not in others [13] . Inconsistencies in the outcomes of SNP association studies suggest that environmental influences or gene-gene interaction may be influential. Compared to wild-type receptors, the PPAR ␥ -Ala variant exhibits reduced binding to DNA and modest impairment of transcriptional activation by pharmacological ligands in vitro [6, 14] , and the PPAR ␣ -Val form shows lower transcriptional activation in transfectants activated with -fatty acids [15] . These findings raise the possibility that differential responses of PPAR gene variants to endogenous ligands might influence plasma variables controlled by target genes.
We hypothesised that carriage of PPARG Pro12Ala and PPARA Leu162Val allelic combinations might influence concentration of plasma lipids according to availability of dietary unsaturated fatty acid ligands. We studied 466 men and women aged 30-70 years in the RISCK study, a highly controlled dietary intervention trial, in which saturated fat was replaced with either monounsaturated fat or CHO in isoenergetic diets [16] . Independent and interactive effects of PPARG Pro12Ala and PPARA Leu162Val genotypes in determination of plasma lipid concentrations were assessed at baseline after a 4-week run-in period on high saturated (HS) fat diet, and after a 24-week period of dietary intervention.
Subjects and Methods

Subjects
Ethical approval for the RISCK study was granted from the National Research Ethics Service and written informed consent from participants was obtained, including subsequent genetic analyses. The study was registered at www.clinicaltrials.gov as ISRCTN29111298. Men and women (age range: 30-70 years) recruited from the general population, attended a clinic in a fasting state at the participating centers (University of Reading, Imperial College London, University of Surrey, the Medical Research Council Human Nutrition Research Centre (MRC-HNR), University of Cambridge, and King's College London) for measurement of height, weight, waist, seated blood pressure, liver function test, glucose and lipid concentrations, and hematology. A score of 6 4 points was required to qualify for entry into the study according to the following point system: a fasting glucose concentration 1 5.5 mmol/l or insulin concentration 1 40 pmol/l = 3 points; body mass index (BMI; in kg/m 2 ) 1 30 or waist 1 102 cm for men and 1 88 cm for women = 2 points; BMI of 25-30 or waist 1 94 cm for men and 1 80 cm (women) = 1 point; treated hypertension = 2 points; systolic blood pressure 1 140 mm Hg = 1 point; diastolic blood pressure 1 90 mm Hg = 1 point; HDL cholesterol concentration ! 1.0 mmol/l for men and ! 1.3 mmol/l for women = 2 points; and serum triacylglycerol concentration 1 1.3 mmol/l = 1 point. Exclusion criteria for this study were as follows: a medical history of ischemic heart disease; a 1 30% 10-year risk of CVD (5); diabetes mellitus; cancer, pancreatitis, cholestatic liver disease, or renal disease; use of lipidlowering drugs; systemic corticosteroids, androgens, phenytoin, erythromycin, or drugs for regulating hemostasis (excluding aspirin); exposure to any investigational agent ^ 30 days before the study; presence of gastrointestinal disorder or use of a drug that is likely to alter gastrointestinal motility or nutrient absorption; a history of substance misuse or alcoholism; a current pregnancy, planned pregnancy, or given birth in the past 12 months; an allergy or intolerance to intervention foods; an unwillingness to follow the protocol or to give informed consent; a weight change of 1 3 kg in the 2 months before the study; intake of 1 1 g eicosapentaenoic and docosahexaenoic acids/day; or smoking 1 20 cigarettes/day. 47.5% of the subjects had metabolic syndrome according to the criteria of the International Diabetes Federation [17] . 549 subjects completed the RISCK study. The current study involved 466 subjects for whom DNA samples were available. Self-reported ethnicity was recorded as White, South Asian, Black African, or other.
Study Design
The RISCK study is a parallel 2 ! 2 factorial design compared with a control intervention [16] . The intervention diets were planned to provide similar intakes of dietary energy but to vary in the amount and type of fats and CHOs. All participants followed a 4-week run-in period during which they consumed a HS fat 'reference diet' before being assigned randomly to the reference diet or one of four isoenergetic dietary interventions designed to lower saturated fat. In this study, the dietary intervention groups differing in CHO quality (high and low glycaemic index) were combined to focus the analyses on the manipulation of dietary fat. The resulting three dietary groups were: HS fat 'reference diet' designed to reflect saturated fat intake in a 'Western' diet [ ϳ 18% of energy saturated fatty acids (SFA), 12% monounsaturated fatty acids (MUFA), 38% total fat, 45% CHO], 'high MUFA (HM) diet' in which SFA was reduced and replaced with MUFA ( ϳ 10% of energy SFA, 20% MUFA, 38% total fat, 45% CHO) and 'low-fat (LF) diet', in which SFA was reduced through replacement of total fat with CHO ( ϳ 10% of energy SFA, 11% MUFA, 28% total fat, 55% CHO). The proportion of PUFA was constant in all three diets ( ϳ 6% of energy). The dietary intervention is described in detail elsewhere [18] . Measurements made after the run-in diet are referred to as 'baseline'. All participants followed the three randomly prescribed diets for 24 weeks, after which a further blood sample was collected and anthropometry measured. Unweighed 4-day food diaries (3 week days and 1 weekend day) were collected to record dietary intakes at baseline and in the third and the final month of the intervention. Nutrient intakes were estimated by using the food-composition database software DINO as described previously [16] . Weight (in light clothing) and height (without shoes) were measured and an indwelling venous cannula was inserted into the forearm.
Blood Analytic Methods
Blood samples for analysis were drawn after a minimum 8-hour overnight fast and serum was stored at -45 ° C until analysed. Fasting lipids were measured as described previously [16] . LDL cholesterol was derived from the Friedwald equation. The proportion of small dense LDL (sdLDL) was measured by ultracentrifugation of the LDL fraction on an iodixanol gradient at the University of Surrey, and compliance to diets was verified by measurement of fasted plasma phospholipid fatty acids by GC at the University of Reading, both as described previously [18] .
DNA Extraction and SNP Genotyping
Buffy coats removed from blood samples were stored in EDTA at -20 ° C. Genomic DNA was extracted from 200 l buffy coat using an Illustra blood genomic prep mini spin kit (GE Healthcare, Amersham, UK), according to manufacturer's instructions. Genotyping was performed in the 466 participants for whom DNA was available. The PPARG Pro12Ala SNP (rs1801282) was genotyped by KBiosciences (Hoddesdon, UK). Genotype accuracy as assessed by inclusion of duplicates in the array was 98% and negative controls (water blanks) were included on each plate. Genotyping success rate was 89%. PPARA Leu162Val (rs1800206) was genotyped by Pyrosequencing (Qiagen, Crawley, UK). Template PCR amplifications were one cycle at 94 ° C for 6 min; 50 cycles at 94 ° C for 1 min, 60 ° C for 45 s and 72 ° C for 1 min; one cycle at 72 ° C for 10 min in a buffer containing 1 ! RedTaq polymerase buffer, 2.5 m M MgCl 2 , 0.4 M dNTP, 200 M primers and 0.2 U RedTaq polymerase. Template primers were as follows: forward: 5 -GCCAGTATTGTCGATTTCACAAGT-3 ; reverse 5 -bio-TTACCTACCGTTGTGTGACATCC-3 . The forward sequencing primer was: 5 -TCGATTTCACAAGTGC-3 . All reagents and primers were from Sigma-Aldrich (Gillingham, Dorset, UK). Genotyping accuracy was 98% and success rate was 97%.
Statistical Analyses
All genotype distributions were tested for deviation from the Hardy-Weinberg equilibrium by a 2 test with 1 d.f. (p 1 0.05). Statistical analyses were carried out using the SPSS version 17.0 for Windows (SPSS Inc, Chicago, Ill., USA). Where needed, variables were log transformed to obtain better approximations of the normal distribution prior to analysis. SNP genotype association with plasma lipid concentration was tested using analysis of covariance (ANCOVA), with age, gender, ethnicity and diet as covariates. Outliers, defined as points 1 2.5 times the interquartile range from the median on the transformed scale at recruitment or after HS diet, were excluded. 3-way ANCOVA was used to test interaction between genotypes and dietary intake of fat. In this model, the dependent variable was the analysed plasma lipid and fixed factors were the genotypes and high MUFA or low fat, with age, gender and ethnicity as covariates. All data presented in text and tables are expressed as means or geometric means 8 SD or 95% CI. Statistical significance was set at p ! 0.05.
Results
The allele and genotype frequencies for PPARG Pro12Ala and PPARA Leu162Val in the 466 RISCK subjects for whom DNA was available are shown in online supplementary table 1 (www.karger.com/doi/10.1159/000336362). Genotype distributions did not deviate from Hardy-Weinberg expectations. In comparison to minor allele frequencies listed on the NCBI SNP database [19] , the PPARG Ala12 allele was more frequent in RISCK Whites than HapMap Europeans (0.076 in HapMap-CEU) and absent in Blacks, as in HapMap-YRI (SubSaharan African). The PPARA Val162 allele was also more frequent in RISCK Whites (0.042 in HapMap-CEU) and absent in Blacks, as in HapMap-YRI trios. There are no comparative data available for the South Asian subjects. As both variant alleles were absent in Black subjects, the subsequent analyses were based on subjects of White European, South Asian and other ethnicities. The characteristics of these 428 participants after the HS baseline reference diet are presented in table 1 .
Diet during the 4-week run-in period to baseline on the HS reference diet was monitored by weighed intake [18] . Table 2 shows plasma lipid measurements at baseline, stratified by PPARG Pro12Ala and PPARA Leu162Val genotypes. Carriers of the PPARG Ala12 allele had 5.4% higher total cholesterol, 5.7% higher LDL cholesterol and 7.3% higher apoB than Pro12 homozygotes, differences which were significant after adjustment for age, gender and ethnic-ity. There were no significant associations of PPARA Leu162Val genotype with plasma lipid concentrations.
Subjects for whom PPARG Pro12Ala and PPARA Leu162Val genotype data were available (n = 365) were divided into four genotype groups defined by presence or absence of the variant alleles. Mean concentrations of plasma lipids with respect to genotype combinations are shown in table 3 . There was a significant interaction between genotypes as determinants D ata is presented for subjects of White European, South Asian and other ethnicities who completed the study and for whom DNA samples were available (n = 428). Apart from ethnicity, values are presented as mean 8 SD, or geometric mean (8 SD) values for triglycerides. All variables were measured at baseline after a 4-week run-in period on reference HS diet. Significance of differences between males and females was determined by the Student t test. a Self-reported ethnicity. Dat a is presented for subjects of White European, South Asian and other ethnicities for whom DNA samples were available (n = 428). Apart from gender, values are presented as mean (95% CI), or geometric mean (95% CI) for triglycerides. All variables were measured at baseline after a 4-week run-in period on reference HS diet. p values for analysis of variance based on a dominant model are adjusted for age, gender, and ethnicity, unless shown.
of total cholesterol concentration after adjustment of all data and p values for gender, age and ethnicity but gene-gene interaction was not significant after correction for multiple testing.
Subjects were randomly assigned to continuation on the HS reference diet, or an isoenergetic diet, in which saturated fat was replaced with either MUFA (HM diet) or CHO (LF diet), for 24 weeks. PUFA intake was equivalent in all diets. There was no significant difference in intake of saturated fat during the run-in between groups randomised to the interventions, and body weight was relatively stable. Further information is provided elsewhere [16, 18] . The changes in plasma %SF and %MUFA differed between the diets over the 24 weeks of intervention. The HM diet group had significantly lower plasma phospholipid %SF than the LF diet group and higher %MUFA, but other fatty acid classes [(n-3) PUFA, (n-6) PUFA and trans FA] were not affected [18] . Total and LDL cholesterol concentrations were significantly lower after consumption of HM and LF than after the HS reference diet. ApoB concentrations differed between treatment groups and were lower after the HM and LF diets than the HS diet. There were no significant changes in plasma triglyceride or sdLDL as a proportion of LDL [16] .
Independent associations of PPARG Pro12Ala or PPARA Leu162Val genotypes with changes in concentrations of plasma lipids with respect to baseline were not significant after randomisation to continued HS reference diet, or switch to HM and LF diets (data not shown).
Investigation of genotype interaction was based on subjects genotyped for both SNPs with measurements of plasma lipids, after HM (n = 212) and LF (n = 216) diets. There was a significant interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes as determinants of plasma LDL cholesterol (p = 0.0002), and sdLDL as a proportion of LDL (p = 0.005), after adjustment for age, gender and ethnicity. Co-carriers of the PPARG Ala12 and PPARA Val162 alleles had 45.7% lower LDL and 53.5% lower sdLDL as a proportion of LDL after the HM diet, compared to the LF diet. We did not test interaction after the parallel SFA diet, as there were no subjects carrying both PPARG Ala12 and PPARA Val162 alleles in this group. Data is presented for subjects of White European, South Asian and other ethnicities for whom PPARG Pro12Ala and PPARA Leu162Val genotype data was available (n = 365). All variables were measured at baseline after a 4-week run-in period on reference HS diet. Values are presented as mean (95% CI), or geometric mean (95% CI) for triglycerides. All data and p values for analysis of variance are adjusted for age, gender, and ethnicity. Interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes was not a significant determinant of total plasma cholesterol (p < 0.05) after correction for multiple testing. Figure 1 shows the follow-up concentration of plasma LDL cholesterol and sdLDL as a proportion of LDL cholesterol after the HM and LF diets, adjusted for baseline concentrations, with respect to PPARG Pro12Ala and PPARA Leu162Val genotype combinations. Mean concentrations of LDL cholesterol and proportion sdLDL (in %) at baseline and at follow-up after HM or LF diets are shown in table 4 .
Discussion
We have shown interactive effects of PPAR ␥ 2 gene PPARG Pro12Ala and PPAR ␣ gene PPARA Leu162Val genotypes as determinants of plasma LDL cholesterol concentration and the proportion as sdLDL, after diets in which SFA was replaced with either MUFA or CHO.
The deleterious effects of dietary SFA on circulating lipids, primarily LDL cholesterol are well known [20] . When MUFA isoenergetically replace SFA in the diet, plasma LDL cholesterol decreases and HDL cholesterol concentration is maintained. HF diets cause significant reductions in triglycerides compared to high-CHO (LF) diets [21, 22] . In RISCK participants, as expected, plasma total and LDL cholesterol and apoB concentrations were significantly lower after consumption of HM and LF than after the HS reference diet. However, unexpectedly, there were no significant reductions in plasma triglyceride concentrations [16] . Several studies have investigated the effects of different nutritional interventions on LDL particle size. Krauss and Dreon [23] found that after 6 weeks on a high-fat (46%) diet, 83% of healthy men had predominantly large, buoyant LDL (pattern A), whereas the remainder had primarily smaller, denser LDL (pattern B). After a LF (24%) diet, 41% with pattern A changed to B, i.e. an increase in the proportion of LDL as sdLDL ( ! 255 Å [24] ) was seen in some but not all subjects, a variability that may reflect a genetic basis. In other studies, switching from a baseline diet rich in saturated fat to diets rich in MUFA, PUFA or a combination [25, 26] also reduced LDL particle size. However, we found no significant change in the proportion of LDL cholesterol as sdLDL after the switch from HS to HM or LF diets. After the 4-week run-in period on HS diet, carriers of the PPARG Ala12 allele had significantly higher plasma total cholesterol, LDL cholesterol and apoB concentrations than Pro12 homozygotes. Ala12 association with an atherogenic lipid profile is consistent with some previous results, but not all. In the most recent meta-analysis including 52,998 subjects, only male Ala12 carriers had significantly increased plasma total cholesterol compared to non-carriers [27] . We tested gene-gender interaction as a determinant of LDL cholesterol concentration, but this was not significant. Accordingly, we did not further test association stratified by gender. The PPARA Leu162Val genotype was not associated with plasma lipids at baseline. Others have reported similarly [13, [28] [29] [30] , but associations of Val162 with higher [11, 31] and lower [32] concentrations of plasma triglycerides have previously been found. We found no significant interaction between PPARA Leu162Val and PPARG Pro12Ala genotypes as determinant of plasma lipid concentrations at baseline, after correction for multiple testing. One other investigation also found no significant interaction between these SNPs in determination of plasma lipid concentrations [33] .
Increased expression of PPAR ␥ mRNA in adipose tissue [34] and PPAR ␣ mRNA and target genes in liver [35] after a high-fat diet in mice suggested that fat intake might influence expression of PPAR targets in humans, with possible impact on associated phenotypes. Neither PPARG Pro12Ala nor PPARA Leu162Val genotypes were independently associated with changes in concentrations of plasma lipids after dietary intervention, although after randomisation, the power to detect significant changes was reduced. Various dietary interactions with PPARG Pro12Ala and PPARA Leu162Val have been reported. Reports of PPARG Pro12Ala interaction with fatty acids as a determinant of plasma lipid concentrations are scarce. An initial study found total fat intake was inversely correlated with total plasma cholesterol in Pro12 homozygotes, but MUFA intake was inversely associated with BMI in Ala12 allele carriers [36] , i.e. the responsiveness of Ala12 carriers depended on the type of fat consumed. Luan et al. [37] previously found greater sensitivity of Ala12 allele carriers to dietary PUFA in determination of BMI. Both findings are compatible with unsaturated fatty acids PP represents subjects homozygous for the PPARG Pro12 allele, and PA + AA carriers of the Ala12 allele. LL represents subjects homozygous for the PPARA Leu162 allele and LV carriers of the Val162 allele.
Mean concentrations (95% CI) of LDL cholesterol and proportion sdLDL (in %) at baseline and follow-up after a 24-week period on HM or LF diets are shown. * Follow-up adjusted for baseline values.
acting as specific ligands for PPAR ␥ [38] and lower transcriptional activity of the PPAR ␥ -Ala variant [6] reducing adipogenesis. Reports of effects of PPARA Leu162Val interaction with fatty acid intake on plasma lipids are inconsistent, including no interaction with PUFA [39] , association of Val162 with higher total and LDL cholesterol after a high PUFA diet [40] and higher triglyceride after low-PUFA intake [39] .
Our study is the first to report significant interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes and diet, as a determinant of plasma LDL cholesterol concentration and proportion as sdLDL. Evidence for influence of PPAR ␥ and PPAR ␣ on plasma lipoprotein concentrations has mainly come from studies of pharmacological ligands in vitro and in vivo. PPAR ␥ agonist thiazolidinediones (TZD) generally reduce triglycerides and increase HDL cholesterol [41] , but LDL cholesterol concentrations either do not change or can increase [42] . The effect of PPAR ␣ agonist fibrates is generally to reduce plasma LDL apoB-100 and increase HDL cholesterol, without significantly affecting LDL cholesterol concentration [43] . If the reported increase in plasma LDL cholesterol by TZDs [42] is a direct effect of PPAR ␥ activation, a possible mechanism could be via insulin-induced gene 2 (INSIG2) , in association with steroid response element binding protein, which controls LDL receptor expression [44] and consequently LDL cholesterol clearance. INSIG2 has PPREs responsive to PPAR ␥ [45] and PPAR ␣ [46] , so carriage of the less active PPAR ␥ -Ala [6] and PPAR ␣ -Val [15] forms would be compatible with a fall in LDL cholesterol concentration in response to a MUFA ligand. All the other genotype combinations showed smaller reductions in LDL cholesterol after the HM diet. Lower LDL cholesterol in carriers of both variants only after the HM diet appears to be a response to increased availability of MUFA.
One of the most consistent effects of TZDs is to increase the mean LDL particle size/reduce LDL density [41] . Were PPAR ␥ to be implicated directly, carriage of the lower activity PPAR ␥ -Ala form would be expected to associate with a higher proportion of small LDL particles. This was found to be the case by Hamada et al. [47] , where PPARG Ala12 carriers had a significantly higher proportion of sdLDL fractions 4-7 independent of lipid concentration. As mentioned previously, dietary intervention studies have shown that variation in dietary fat and CHO can strongly influence expression of the small LDL phenotype [23] , with high fat intake associated with an increase in large LDL and decrease in sdLDL. Bouchard-Mercier et al. [48] found no significant change in LDL peak particle diameter in PPARG Pro12 homozygotes or Ala12 carriers after high SFA intake, but a significant increase in LDL peak particle diameter in Ala12 carriers after high intake of PUFA, which unlike SFA are PPAR ␥ activators [38] . We, however, found no independent association of Ala12 with sdLDL proportion neither at baseline after run-in on HS diet, nor after 24 weeks on HM or LF diets. Bouchard-Mercier et al. [48] found that high SFA intake was associated with larger LDL particle size in PPARA Leu162 homozygotes, compatible with other reports of reduced LDL particle size on switching from SFA-rich to MUFA-rich diets [25, 26] . However, contrary to the general observation, in Val162 carriers, high SFA intake was associated with a higher proportion of sdLDL. Fibrate ligands of PPAR ␣ can reduce production of VLDL [43] and lower sdLDL [49, 50] , so in carriers of the less active PPAR ␣ -Val form, activation by dietary ligands could result in a shift to a higher proportion of sdLDL. However, we found no significant change in the proportion of sdLDL in Val162 carriers compared to Leu162 homozygotes on switching from the HS diet at baseline to the HM or LF diets, but a significant reduction in the proportion of sdLDL in carriers of both PPARA Val162 and PPARG Ala12 alleles after the HM diet. This cannot be explained by reduced activity of both variants, because as indicated above, this would be expected to lead to a higher proportion of sdLDL. Only one other study has examined PPARG Pro12Ala and PPARA Leu162Val interaction after dietary intervention: a 2.5-year low-energy diet in obese women, in whom there were significant favourable changes in lipid profile, but no significant interactive effects at baseline or at follow-up [51] .
The strength of our study lies in its design as a randomised, tightly controlled feeding trial with high adherence and retention rates and diets with practical relevance to the general population. Limitations include reduced power after randomisation to dietary treatments, compared to that at baseline, with small numbers carrying both variants. However, our ANOVA model used the variability of the whole dataset to measure the background variation and produced evidence of a significant effect of gene-gene interaction on LDL cholesterol and proportion as sdLDL. Nevertheless, the significance should be treated with caution and confirmation awaits replication in a larger sample.
In conclusion, we first showed that plasma lipid measurements can be affected by dietary factors. However, a single measurement may not reflect the long-term exposure to altered lipid concentrations which imposes disease risk [52] . In contrast, genotypes are invariant and can exert an effect on lipid levels over a lifetime, although even in well replicated cases, the contribution of each allele to phenotypic variance is usually small and single genetic markers may not add information on disease risk beyond that provided by measurement of biochemical traits. Reports suggest that the predictive value of genetic markers can be increased by combining information from multiple loci [53, 54] . We have shown a modest effect of interaction between PPARG Pro12Ala and PPARA Leu162Val in determination of LDL cholesterol concentration and proportion as sdLDL after a HF diet, but no effect associated with the individual SNPs. A combination of several polymorphisms could provide information about cardiovascular risk beyond plasma lipid levels and allow for early identification and treatment of susceptible individuals. The same principle applies to prediction of individual responses to diet which may moderate disease risk. Verification of genetic susceptibility and targeting of dietary interventions will require larger scale randomised clinical trials.
